Congress recently began hearings on proposals to combat opioid abuse. Our policy analyst weighs in.
Two health plans are sharing the wealth—in this case, drug discounts from manufacturers—with consumers at point of sale.
How skipping industry acronyms and jargon and using simple terminology will eliminate confusion and misinterpretation.
A Surescripts survey reveals the need for more interoperable access to patient data in three major areas.
An ONC report finds that more patients are engaged with their health records. Here’s why.
To get a pulse on the U.S.
Douglas Long, vice president of industry relations at Durham, NC-based IQVIA, a newly named company after the merger of IMS Health and Quintiles, discussed pharmaceutical marketplace trends during the headline session at the Academy of Ma
Gene therapy, which got its start in the 1960s, is finally starting to take hold.
Expiring patents and biosimilar developments are creating big market opportunities within the specialty drug space.
High-cost treatments for rheumatoid arthritis has fueled the need to better understand their value to healthcare systems and patients.